Biotech Values

[dewophile]

The 31% figure is impressive insofar as peg-IFN by itself has a 48w seroconversion rate of only 5-10%

To be clear the 31% is an end of treatment figure, not sustained rate off therapy. sustained rates of SAg loss w peg-IFN is generally felt to be 5% or less as far as I know, although it may be higher in certain special populations like perhaps lower baseline levels etc so I assume that is where you are getting the 5-10%?

Of course, a 48w regimen of VIR-2219 + peg-IFN won’t be any easier to tolerate than 48w of peg-IFN monotherapy, so this regimen is still far from the ultimate answer for treating chronic HBV.

They only tested 48 weeks because shorter regimens had very low rates of HBSAg loss (and none without peg-IFN).